← All indications
Burns
Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.
Subtype terms (6)
More specific conditions that are subtypes of Burns in the MeSH hierarchy.
- Burns, Chemical
3 drugs (1 approved, 2 experimental)
- Burns, Electric
1 drug experimental
- Burns, Inhalation
- Erythema Ab Igne
- Eye Burns
1 drug approved
- Sunburn
36 drugs (22 approved, 14 experimental)
Drugs by status
Approved for this indication (33)
- phenylalanine
- leptospermum honey
- benzocaine
- diphenhydramine
- ethanol
- Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen
- albumin (Human)
- hypericum perforatum
- iodine
- l-alanine
- leucine
- mafenide acetate
- nanocrystalline silver
- lidocaine
- threonine
- l-histidine
- l-isoleucine
- menthol
- silver fluoride
- valine
- isopropyl alcohol
- anacaulase
- calendula officinalis
- nitrofural
- sutilains
- lanolin
- pramocaine
- tetracycline
- bacitracin
- silver sulfadiazine
- +3 more
Phase 4 trials (46)
- ringer's lactate
- propofol
- vitamin d3
- petrolatum, white
- urea
- cefazolin
- ketamine
- oxycodone
- ceftolozane
- vitis vinifera
- glycerin
- esketamine
- daptomycin
- nystatin
- oliceridine
- piperacillin
- potassium chloride
- remimazolam
- silicone
- sorbitol
- bupivacaine
- fluconazole
- glucose
- vancomycin
- vitamin k
- amphotericin b
- collagenase clostridium histolyticum
- gentamicin
- cerium nitrate
- fenofibrate
- +16 more
Phase 3 trials (40)
- nitrous oxide
- amnion-derived cellular cytokine
- heparin
- kynurenic acid
- vitamin e
- amniotic membrane
- oxandrolone
- exenatide
- dehydroepiandrosterone
- ibuprofen
- somatropin
- l-glutamine
- glycopyrronium
- insulin human
- epidermal growth factor
- mecasermin
- nitrogen
- octenidine
- oleogel-s10
- propranolol
- coagulation factor viia (recombinant)
- hyaluronic acid
- immune globulin (human)
- sitagliptin
- silver nitrate
- estradiol
- clonidine
- cellulose
- ciprofloxacin
- autologous keratinocytes
- +10 more
Phase 2 trials (52)
- metformin
- melatonin
- dalfampridine
- afn-12520000
- human fibrin
- banana leaf
- procaine benzylpenicillin
- tobramycin
- thrombin (bovine)
- bvs857
- cetirizine
- essential oils
- rosuvastatin
- hydrocolloid
- icx-rhy-013
- nefopam
- vitamin c
- opebacan
- pirfenidone
- bimatoprost
- surfactant
- platelet derived growth factor
- ramelteon
- rhu-pgelsolin
- rph201
- serlopitant
- sesame oil
- telavancin
- tt-173
- zolpidem
- +22 more
Phase 1 trials (17)
Other trials (32)
- iron
- sucrose
- acellular dermal matrix
- Bismuth Subcitrate Potassium
- capsaicin
- epiceram
- folic acid
- gabapentin
- histamine
- cyanocobalamin
- icosapent ethyl
- indocyanine green
- inulin
- whey protein
- caffeine
- honey
- testosterone
- tramadol
- enoxaparin
- egg albumin-derived peptide
- triamcinolone
- hypochlorous acid
- silvazine
- pregabalin
- tea
- unfractionated heparin
- human dehydrated amnion chorion allograft
- abobotulinumtoxinA
- b multivitamins
- zinc
- +2 more
Organizations
Organization Involved with Phase 4 Indications (35)
- Fresenius
- Merck
- Molnlycke Health Care AB
- GeneScience Pharmaceuticals Co., Ltd.
- Healthpoint
- University of Pittsburgh
- Centre Hospitalier Saint Joseph Saint Luc de Lyon
- Georgetown University
- HealthPartners Institute
- Loyola University
- Shriners Hospitals for Children
- Texas Tech University
- University of Kansas
- University of Louisville
- University of Sorocaba
- University of Alberta
- University of Birmingham
- University of Virginia
- University of Zurich
- Association of Dutch Burn Centres
- Capital Medical University
- Zhejiang University
- Department of Defense
- Saint Joseph Saint Luc Hospital
- Jiao Tong University
- University of Montreal
- University of Nantes
- National Autonomous University of Mexico
- Linkoping University
- Joseph M. Still Research Foundation, Inc.
- +5 more
Organization Involved with Phase 3 Indications (24)
- Birken AG
- Cumberland Pharmaceuticals
- MediWound Ltd
- Modern Cell and Tissue Technology
- National Institute of General Medical Sciences (NIGMS)
- National Science and Technology Development Agency, Thailand
- United States Army
- Chulalongkorn University
- King Edward Medical University
- University of Hamburg
- University of the Philippines
- Xiamen University
- Azidus
- Sun Yat-Sen University
- University of Texas, Galveston
- Federal University of Ceara
- Hangang Sacred Heart Hospital
- University of Paris
- Humboldt University
- GCP-Service International Ltd. & Co. KG
- American Burn Association
- Air Liquide
- Tishreen University
- Abouqir General Hospital
Organization Involved with Phase 2 Indications (49)
- A.A. Partners, LLC
- Regeneron
- Sanofi
- Novartis
- Anterogen Co., Ltd.
- Baxalta
- Fibrocell Technologies, Inc.
- Vyne Therapeutics Inc.
- Noveome Biotherapeutics
- Regenera Pharma Ltd
- Skingenix, Inc.
- Amarantus BioScience Holdings, Inc.
- Sunnybrook Health Sciences Centre
- University of Arizona
- American Scitech International
- Belarusian Medical Academy of Post-Graduate Education
- Harvard University
- University of Washington
- Kunming Medical University
- Ohio State University
- Universidad Autonoma de Nuevo Leon
- University of Kentucky
- University of Padova
- University of South Alabama
- University of South Florida
- University of Toronto
- Yale University
- Tel Aviv University
- University of California, Davis
- University of California, Irvine
- +19 more
Organization Involved with Phase 1 Indications (17)
- Pfizer
- Biotec Pharmacon ASA
- GlaxoSmithKline
- University of Manitoba
- Memorial Medical Center
- Oregon State University
- Southern Illinois University
- The Baruch Padeh Medical Center, Poriya
- University of Miami
- University of Bergen
- University of Zagreb
- Zhejiang Chinese Medical University
- Technion University
- Ben Gurion University
- Kaneka Corporation
- Guiyang Hospital of Stomatology
- Stomatological Hospital of Guiyang
Organization Involved with Other Experimental Indications (17)
- Bio-medical Carbon Technology Co., Ltd.
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- Cairo University
- Centro Nacional de Quemados, Uruguay
- Chang Gung University
- Universidad de Murcia
- University of Iowa
- University of Milan
- Wake Forest University
- University of Ulsan
- The Spectrum Health Group
- National Taiwan University
- University of Sao Paulo
- University of Liege
- Government of Taiwan
- Realm Therapeutics